RVL Pharmaceuticals plc (RVLPQ)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Brian A. Markison | Chairman, President, CEO & Principal Financial Officer | 525k | -- | 1959 |
| Mr. James D. Schaub | Executive VP & COO | 367.2k | -- | 1982 |
| Mr. Christopher A. Klein | General Counsel | 367.2k | -- | 1964 |
| Mr. Michael J. DePetris | Principal Accounting Officer | -- | -- | 1977 |
| Mr. Jarret Miller | Executive Vice President of Human Resources | -- | -- | -- |
| Scott Schroppe | Secretary | -- | -- | -- |
RVL Pharmaceuticals plc
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 125
Description
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Corporate Governance
Upcoming Events
October 28, 2024 at 12:30 PM UTC - November 2, 2024 at 12:30 PM UTC
RVL Pharmaceuticals plc Earnings Date
Recent Events
November 20, 2023 at 12:00 AM UTC
25-NSE: Notification filed by national security exchange to report the removal from listing and registration of matured